The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages

  Abimbola, Taiwo O ^a   Marston, Barbara J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral therapy; Cost; Cost effectiveness; Cotrimoxazole; HIV; Opportunistic infection

Indexed keywords

AMOXICILLIN; ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; CEFTRIAXONE; COTRIMOXAZOLE;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84862118318     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182478dc0     Document Type: Article

References (46)

1. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report. 2010.
2. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
3. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
4. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
5. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18-26.
6. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999;353:1463-1468. (Pubitemid 29204363)
7. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434. (Pubitemid 39370718)
8. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprimsulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-1475. (Pubitemid 29204364)
9. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207; quiz CE201-204.
10. Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS. 2010;24:1709-1716.
11. Lowrance D, Makombe S, Harries A, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007;46:56-61. (Pubitemid 47507434)
12. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375:1278-1286.
13. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS. 2003;17:575-584. (Pubitemid 36293111)
14. Badri M, Ehrlich R, Wood R, et al. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS. 2001;15:1143-1148. (Pubitemid 32549865)
15. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-1189. (Pubitemid 18058829)
16. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
17. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367:1256-1261.
18. van Oosterhout JJ, Laufer MK, Perez MA, et al. Pneumocystis pneumonia in HIV-positive adults, Malawi. Emerg Infect Dis. 2007;13:325-328. (Pubitemid 46193185)
19. Campbell J, Tappero J, Degerman R, et al. HIV-infected Ugandans on HAART with CD4 cell counts over 200 cells/mm3 who discontinue cotrimoxazole have increased risk of malaria and diarrhea. Paper presented at: HIV Implementers' Meeting 2008; Kampala, Uganda. Abstract B7-3085.
20. Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr. 2007;44:336-343. (Pubitemid 46328352)
21. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and costeffectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS. 2005;19:1299-1308. (Pubitemid 41224899)
22. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med. 2006;355:1141-1153. (Pubitemid 44394920)
23. Ryan M, Griffin S, Chitah B, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008; 22:749-757. (Pubitemid 351450644)
24. WHO. Co-trimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults. Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2006.
25. Date AA, Vitoria M, Granich R, et al. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88:253-259.
26. HEALTHQUAL. The HIVQUAL International Update. Special Issue: Cotrimoxazole preventive therapy. 2009; Supplemental (Spring).
27. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
28. Watera C, Todd J, Muwonge R, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr. 2006;42: 373-378. (Pubitemid 44050018)
29. Alemu AW, Sebastian MS. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action. 2010;3.
30. WHO. Global Price Reporting Mechanism: Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to March 2010.
31. International Drug Price Indicator Guide. Geneva, Switzerland: WHO; 2009; Available at: http://erc.msh.org.
32. WHO. CHOosing Interventions that are Cost Effective (WHOCHOICE), 2005: Results of Unit Costs for patient services for the 14 GBD Regions. Geneva, Switzerland: WHO, 2005. Available at: http://www.who.int/choice/costs/unit- regions/en/index.html. Accessed March 29, 2011.
33. Rosen S, Long L, Fox M, et al. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008;48:334-344.
34. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV (Review). Cochrane Database Syst Rev. 2003: CD003508.
35. Haddix AC, Teutsch SM, Corso PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press. 2003.
36. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001; 10:779-787. (Pubitemid 34041389)
37. Andrews JR, Lawn SD, Rusu C, et al. Cost-effectiveness of Xpert MTB/RIF for screening for tuberculosis prior to antiretroviral therapy in South Africa. Paper presented at: 6th IAS Conference on HIV Pathogenesis Treatment and Prevention; 2011; Rome, Italy. Abstract MOAD0102.
38. Bachmann MO. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care. 2006;18:109-120. (Pubitemid 41780169)
39. Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359:1635-1643.
40. Currie CS, Floyd K, Williams BG, et al. Cost, affordability and costeffectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health. 2005;5:130.
41. Loubiere S, Meiners C, Sloan C, et al. Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS. 2010;5:225-231.
42. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis. 2007;11:747-754. (Pubitemid 47056983)
43. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African costeffectiveness study. Antivir Ther. 2006;11:63-72.
44. Bendavid E, Wood R, Katzenstein DA, et al. Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2009;52:106-113.
45. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc. 2006;4:20.
46. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009; 151:157-166.